๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prevention of In Vivo Alloreactions by Adoptive Immunotherapy with Lymphokine-Activated Killer Cells

โœ Scribed by JOSEPH KAPLAN; JOSEPH UBERTI

Book ID
119866215
Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
124 KB
Volume
636
Category
Article
ISSN
0890-6564

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Immunotherapy of cancer with lymphokines
Immunotherapy of cancer with lymphokines and lymphokine-activated killer cells
โœ John W. Yarbro ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 996 KB

Our expanding knowledge of the immune system has provided a basis of rationality for immunotherapy . Some non-specific immunotherapy has achieved the status of standard treatment: interferon in hairy cell leukemia and chronic myelogenous leukemia, BCG in bladder cancer, and levamisole in colon cance

Adoptive immunotherapy with lymphokine-a
Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
โœ Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsu ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 591 KB

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days